Revisiting the prognostic role of gallium scintigraphy in low-grade non-Hodgkin's lymphoma

被引:30
|
作者
Gallamini, A
Biggi, A
Fruttero, A
Pugno, F
Cavallero, G
Pregno, P
Grasso, M
Farinelli, C
Leone, A
Gallo, E
机构
[1] S Croce Hosp, Div Haematol, I-12100 Cuneo, Italy
[2] S Croce Hosp, Dept Nucl Med, I-12100 Cuneo, Italy
[3] S Croce Hosp, Dept Pathol, I-12100 Cuneo, Italy
[4] S Croce Hosp, Dept Radiol, I-12100 Cuneo, Italy
关键词
low-grade non-Hodgkin's lymphoma; gallium-67; scan; prognosis; transferrin receptor;
D O I
10.1007/s002590050180
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
The purpose of this study was threefold: to evaluate the role of gallium-67 scintigraphy in the staging of low-grade non-Hodgkin's lymphomas (LGNHL), to assess the relationship between the expression of CD71 on the surface of the neoplastic cells and the Ga-67 uptake by the tumour, and to establish the contribution of Ga-67 scan in defining the prognosis of LGNHL. Forty-eight patients with untreated LGNHL diagnosed in a single institution over a decade were reviewed, The end point of the study was survival of the patients according to the scintigraphic Ga-67 score at diagnosis. In addition to Ga-67 scan, other prognostic variables were studied, relating to the neoplastic burden, the biology of the tumour and the host. Univariate and multivariate analyses were used. Ga-67 scan identified only 116/286 (41%) nodes involved by lymphoma that were detected by clinical examination or computed tomography scan. A scintigraphic scoring system with an arbitrary cut-off value of 3 (high scan score) was able to predict patients with a dismal prognosis: with a mean follow-up of 47 months (range: 1-146 months) the median survival time was 28 months in patients with a high scan score and 74 months in patients with a low scan score (P=0.002), CD71 values were 27.4%+/-14.9% (mean +/-SD) in the former and 8.9%+/-7.2% in the latter (P=0.0001). Only performance status and extranodal sites were significant variables for prognosis in multivariate analysis. It is concluded that Ga-67 scan is inaccurate in staging but might be very important in defining the prognosis in LGNHL, in association with other prognostic variables.
引用
收藏
页码:1499 / 1506
页数:8
相关论文
共 50 条
  • [41] Treatment response assessment and prognostic value of Gallium-67 scintigraphy in pediatric non-Hodgkin's lymphoma
    Meristoudis, G.
    Ilias, I.
    Giannakopoulos, V.
    Batsakis, C.
    Paschou, A.
    Roussis, C.
    Christakopoulou, J.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2009, 36 : S436 - S436
  • [42] The International Prognostic Index predicts outcome after histological transformation of low-grade non-Hodgkin lymphoma
    Micallef, Ivana N. M.
    Remstein, Ellen D.
    Ansell, Stephen M.
    Colgan, Joseph P.
    Inwards, David J.
    Johnston, Patrick B.
    Lewis, Jason T.
    Markovic, Svetomir N.
    Porrata, Luis F.
    White, William L.
    Witzig, Thomas E.
    Ristow, Kay
    Habermann, Thomas M.
    LEUKEMIA & LYMPHOMA, 2006, 47 (09) : 1794 - 1799
  • [43] Current therapeutic approaches to patients with newly diagnosed low-grade non-Hodgkin's lymphoma
    Gregory, Stephanie A.
    SEMINARS IN HEMATOLOGY, 2007, 44 (03) : S7 - S11
  • [44] Radiotherapy for stage I-III nodal low-grade non-Hodgkin's lymphoma
    Ott, OJ
    Rödell, C
    Gramatzki, M
    Niedobitek, G
    Sauer, R
    Grabenbauer, GG
    STRAHLENTHERAPIE UND ONKOLOGIE, 2003, 179 (10) : 694 - 701
  • [45] Secondary myelodysplastic syndrome after fludarabine therapy of a low-grade non-Hodgkin's lymphoma
    Misgeld, E
    Germing, U
    Aul, C
    Gattermann, N
    LEUKEMIA RESEARCH, 2001, 25 (01) : 95 - 98
  • [46] Phase I study of fludarabine and paclitaxel for the treatment of low-grade non-Hodgkin's lymphoma
    Younes, A
    Rodriguez, MA
    McLaughlin, P
    North, L
    Sarris, AH
    Pate, O
    Hagemeister, FB
    Romaguera, J
    Preti, A
    Bachier, C
    Cabanillas, F
    LEUKEMIA & LYMPHOMA, 1997, 26 (1-2) : 77 - 82
  • [47] Hypocomplementemic urticaria with underlying low-grade non-Hodgkin's B-cell lymphoma
    Aldridge, C
    Choudhury, M
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2005, 52 (03) : P140 - P140
  • [48] A first-line treatment of low-grade non-Hodgkin's lymphoma with BACOP regimen
    Luisi, D
    Leva, T
    Malorgio, F
    Di Stefano, P
    Federico, M
    Silingardi, V
    Lombardo, M
    ANNALS OF ONCOLOGY, 2000, 11 : 53 - 53
  • [49] Rituximab in the treatment of patients with relapsed low-grade or follicular non-Hodgkin's lymphoma.
    Capote, FJ
    Bernabé, R
    Martin, MV
    Porta, J
    Almagro, M
    Moreno-Nogueira, JA
    Gil, JL
    EUROPEAN JOURNAL OF CANCER, 1999, 35 : S90 - S90
  • [50] Gemcitabine as a single agent in the treatment of relapsed or refractory low-grade non-Hodgkin's lymphoma
    Dumontet, C
    Morschhauser, F
    Solal-Celigny, P
    Bouafia, F
    Bourgeois, E
    Thieblemont, C
    Leleu, X
    Hequet, O
    Salles, G
    Coiffier, B
    BRITISH JOURNAL OF HAEMATOLOGY, 2001, 113 (03) : 772 - 778